Research Library 

1980 — early teratogenic signal (valproate exposure)

• Dieterich E. et al. (1980)
  Congenital anomalies in children of epileptic mothers and fathers
  https://doi.org/10.1055/s-2008-1071396
  → Early recognition of anticonvulsant teratogenic risk
• Dalens B. & Raynaud E.J. (1980)
  Teratogenicity of valproic acid
  https://doi.org/10.1016/S0022-3476(80)80517-8
  → One of the first reports linking valproate to malformations

 

1981–1983 — pre-syndrome case reports

• Gomez M.R. (1981)
  Possible teratogenicity of valproic acid
  https://doi.org/10.1016/S0022-3476(81)80743-3

1984 — first definition of

Fetal Valproate Syndrome (FVS)

• DiLiberti J.H. et al. (1984)
  The fetal valproate syndrome
  https://doi.org/10.1002/ajmg.1320190308
  → First formal syndrome description

1987 — recognition of a distinct phenotype

• Winter R.M. et al. (1987)
  Fetal valproate syndrome: is there a recognisable phenotype?
  https://doi.org/10.1136/jmg.24.11.692
  → Establishes consistent dysmorphic pattern

1988 — phenotype confirmation & expansion

• Ardinger H.H. et al. (1988)
  Verification of the fetal valproate syndrome phenotype
  https://doi.org/10.1002/ajmg.1320290123
  → Confirms reproducible syndrome definition
• D. et al. (1988)
  Congenital abnormalities in valproate-exposed siblings
  https://doi.org/10.1002/ajmg.1320310214

 

1995 — major clinical synthesis (classic FVS paper)

• Clayton-Smith J. & Donnai D. (1995)
  Fetal valproate syndrome
  https://doi.org/10.1136/jmg.32.9.724
• Landmark description of facial + developmental phenotype
  https://pmc.ncbi.nlm.nih.gov/articles/PMC1051674/

2000 — introduction of broader umbrella:

Fetal Anticonvulsant Syndrome (FACS)

• Moore S.J. et al. (2000)
  A clinical study of 57 children with fetal anticonvulsant syndromes
  https://doi.org/10.1136/jmg.37.7.489
  → Introduces multisyndromic anticonvulsant exposure model

2002 — multisystem expansion (eye + neurodevelopment)

• Glover S.J. et al. (2002)
  Ophthalmic findings in fetal anticonvulsant syndrome(s)
  https://doi.org/10.1016/S0161-6420(02)00959-4

2005 — autism link within FACS

• Rasalam A.D. et al. (2005)
  Fetal anticonvulsant syndrome associated autistic disorder
  https://doi.org/10.1017/S0012162205001076

2009 — mechanism review (valproate embryopathy)

• Ornoy A. (2009)
  Valproic acid in pregnancy: teratogenic risk review
  https://doi.org/10.1016/j.reprotox.2009.02.014
  → Key mechanistic synthesis of valproate embryopathy

 

2014 — expansion of phenotype (ocular coloboma)

• Jackson A. et al. (2014)
  Ocular coloboma and foetal valproate syndrome
  https://pubmed.ncbi.nlm.nih.gov/24584103/
  https://doi.org/10.1097/MCD.0000000000000028
  → Expands dysmorphic spectrum

2017 — modern clinical reviews

• Mutlu-Albayrak H. et al. (2017)
  Fetal Valproate Syndrome
  https://doi.org/10.1016/j.pedneo.2016.01.009
• Wiedemann K. et al. (2017)
  “Fetal Valproate Syndrome – Still a Problem Today”
  https://pubmed.ncbi.nlm.nih.gov/29073690/

 

2018–2019 — modern cohort + neurodevelopment evidence

• R.L. et al. (2019)
  Intellectual functioning in clinically confirmed FVS
  https://doi.org/10.1016/j.ntt.2018.11.003
  https://pmc.ncbi.nlm.nih.gov/articles/PMC6642533/
  → Major IQ reduction and developmental impairment evidence
• Mohd Yunos H. & Green A. (2018)
  Irish cohort study
  https://doi.org/10.1007/s11845-018-1757-6

 

2019 — official modern terminology:

Fetal Valproate Spectrum Disorder (FVSD)

• Clayton-Smith J. et al. (2019)
  Diagnosis and management of FVSD
  https://doi.org/10.1186/s13023-019-1064-y
• → Establishes “spectrum disorder” model replacing rigid syndrome concept
  https://ojrd.biomedcentral.com/articles/10.1186/s13023-019-1064-y

 

2021 — epigenetic mechanism model

• Parodi C. et al. (2021)
  Chromatin imbalance in FVSD
  https://www.frontiersin.org/articles/10.3389/fcell.2021.654467/full

 

2023 — lifespan neurodevelopment outcomes

• Bluett-Duncan M. et al. (2023)
  Neurodevelopment in FVSD
  https://eprints.ncl.ac.uk/293531/